A Study to Evaluate Lenti-HPV-07 Immunotherapy Against HPV+ Cervical or Oropharyngeal Cancer

The goal of this clinical trial is to learn about the safety and efficacy of a potential new treatment called Lenti-HPV-07 in patients with a cancer induced by Human Papilloma Virus (HPV). The main questions aim to answer are: * Is Lenti-HPV-07 safe? * Does Lenti-HPV-07 induce an immune response? Participants will be assigned to a group based on their cancer type * either study drug group A: recurrent and/or metastatic cancer * or study drug group B: newly diagnosed with locally advanced cancer After they finish the study treatment, they will be followed for up to 1 year. Follow-up visits

Trial Details

NCT ID
NCT06319963
Phase
PHASE1 / PHASE2
Sponsor
Theravectys S.A.
Status
RECRUITING
Cancer Type
HPV Positive Head and Neck Cancer
Interventions
  • Two IM injections Lenti-HPV-07
  • One IM injection Lenti-HPV-07
Locations (sample)
  • Orlando, Florida, United States|28.53834,-81.37924
  • Tampa, Florida, United States|27.94752,-82.45843
  • Tampa, Florida, United States|27.94752,-82.45843
  • Tulsa, Oklahoma, United States|36.15398,-95.99277

Key Eligibility Criteria

  • histologically confirmed invasive HPV-related oropharyngeal or cervical cancer
  • ECOG performance status of 0 or 1
  • adequate hepatic, renal, pulmonary, and bone marrow/hematological function

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find HPV Positive Head and Neck Cancer Trials on Trialify →